🔗 Share this article

Chancellor Reeves has revealed she is preparing "focused measures to deal with cost of living issues" in the forthcoming Budget.

During an interview with media outlets, she stated that lowering inflation is a joint responsibility of both the government and the Bank of England.

The United Kingdom's price growth is expected to be the most elevated among the Group of Seven industrialized countries this year and the following year.

Potential Utility Cost Interventions

It is understood the administration could take action to reduce utility costs, for instance by reducing the present 5% level of value-added tax applied on energy supplies.

A further possibility is to lower some of the regulatory levies presently added to household expenses.

Fiscal Constraints and Expert Expectations

The government will obtain the latest assessment from the official forecaster, the OBR, on Monday, which will clarify how much scope there is for such measures.

The view from most economists is that Reeves will have to declare higher taxes or budget cuts in order to fulfill her declared borrowing rules.

Earlier on Thursday, analysis suggested there was a £22 billion gap for the chancellor to address, which is at the more modest range of projections.

"There's a collective job between the Bank of England and the government to continue tackling some of the drivers of inflation," the Chancellor told reporters in the US capital, at the conferences of the International Monetary Fund and global financial institution.

Revenue Commitments and International Issues

While much of the attention has been on probable tax rises, the Treasury chief said the most recent information from the OBR had not changed her pledge to manifesto promises not to increase rates on earnings tax, VAT or social security contributions.

She blamed an "unpredictable world" with growing international and trade concerns for the Budget revenue measures, likely to be directed on those "with the broadest shoulders."

International Trade Disputes

Addressing concerns about the UK's economic relations with the Asian nation she said: "Our security interests invariably come first."

Recent statement by China to strengthen export controls on rare earths and other resources that are crucial for advanced tech manufacturing led American leader the US President to suggest an additional 100% tariff on goods from the Asian country, raising the possibility of an full-scale trade war between the two economic giants.

The American finance chief described the Chinese move "commercial pressure" and "a international production control attempt."

Questioned on considering the American proposal to join its battle with the Asian nation, the Chancellor said she was "extremely troubled" by China's measures and encouraged the Chinese government "to avoid restrictions and limit trade."

She said the decision was "harmful for the world economy and causes further obstacles."

"It is my opinion there are fields where we should confront China, but there are also valuable prospects to export to Chinese markets, including financial services and other areas of the economic system. We've got to maintain that balance correct."

The Treasury chief also confirmed she was working with G7 counterparts "on our own critical minerals approach, so that we are reduced dependence."

NHS Drug Costs and Funding

Reeves also recognized that the price the National Health Service spends on drugs could increase as a result of ongoing negotiations with the Trump administration and its drugs companies, in exchange for lower tariffs and capital.

Some of the world's largest pharmaceutical manufacturers have said recently that they are either halting or canceling investments in the United Kingdom, with some attributing the modest returns they are getting.

Last month, the government science advisor said the cost the NHS spends on drugs would must rise to halt businesses and drug research funding departing from the United Kingdom.

The Chancellor told the BBC: "We have seen as a result of the payment system, that clinical trials, recent pharmaceuticals have not been offered in the United Kingdom in the extent that they are in other EU nations."

"Our aim is to ensure that people receiving care from the National Health Service are able to access the top life-saving drugs in the world. And so we are reviewing this situation, and... seeking to obtain additional funding into the UK."